These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 21520358)
1. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. Raki M; Sarkioja M; Escutenaire S; Kangasniemi L; Haavisto E; Kanerva A; Cerullo V; Joensuu T; Oksanen M; Pesonen S; Hemminki A J Gene Med; 2011 May; 13(5):253-61. PubMed ID: 21520358 [TBL] [Abstract][Full Text] [Related]
2. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen MT; Kanerva A; Hemminki A Gene Ther; 2008 Jun; 15(12):921-9. PubMed ID: 18401431 [TBL] [Abstract][Full Text] [Related]
6. Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Kuriyama S; Tominaga K; Kikukawa M; Tsujimoto T; Nakatani T; Tsujinoue H; Okuda H; Nagao S; Mitoro A; Yoshiji H; Fukui H Gene Ther; 1999 May; 6(5):749-57. PubMed ID: 10505097 [TBL] [Abstract][Full Text] [Related]
7. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. Koski A; Bramante S; Kipar A; Oksanen M; Juhila J; Vassilev L; Joensuu T; Kanerva A; Hemminki A Mol Ther; 2015 Oct; 23(10):1641-52. PubMed ID: 26156245 [TBL] [Abstract][Full Text] [Related]
8. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Myhre S; Henning P; Granio O; Tylö AS; Nygren PA; Olofsson S; Boulanger P; Lindholm L; Hong SS Gene Ther; 2007 Feb; 14(4):376-81. PubMed ID: 17036056 [TBL] [Abstract][Full Text] [Related]
9. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. Rojas LA; Condezo GN; Moreno R; Fajardo CA; Arias-Badia M; San Martín C; Alemany R J Control Release; 2016 Sep; 237():78-88. PubMed ID: 27388756 [TBL] [Abstract][Full Text] [Related]
10. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451 [TBL] [Abstract][Full Text] [Related]
11. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776 [TBL] [Abstract][Full Text] [Related]
12. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Koski A; Raki M; Nokisalmi P; Liikanen I; Kangasniemi L; Joensuu T; Kanerva A; Pesonen S; Alemany R; Hemminki A Mol Ther; 2012 Jan; 20(1):221-9. PubMed ID: 22044933 [TBL] [Abstract][Full Text] [Related]
13. Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology. Yu B; Dong J; Wang C; Wang Z; Gao L; Zhang H; Wu J; Kong W; Yu X J Gen Virol; 2014 Jul; 95(Pt 7):1564-1573. PubMed ID: 24764358 [TBL] [Abstract][Full Text] [Related]
14. Development of transcriptionally regulated oncolytic adenoviruses. Ko D; Hawkins L; Yu DC Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536 [TBL] [Abstract][Full Text] [Related]
15. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors. Zepeda M; Wilson JM Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637 [TBL] [Abstract][Full Text] [Related]
16. Targeting of adenoviral vectors through a bispecific single-chain antibody. Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021 [TBL] [Abstract][Full Text] [Related]
17. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses. Bucurescu S Acta Pharm; 2010 Dec; 60(4):407-13. PubMed ID: 21169133 [TBL] [Abstract][Full Text] [Related]